Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Servier (Neuilly-sur-Seine, France) granted Amgen Inc. (NASDAQ:AMGN) U.S. commercialization rights to Servier's cardiovascular drug Procoralan ivabradine. The selective
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury